BioAffinity Technologies Presents Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies presented research on a potential broad-spectrum cancer therapy at the 2025 RNA Therapeutics Conference. The therapy uses small interfering RNAs to selectively kill cancer cells by targeting cell surface receptors CD320 and LRP2. The data demonstrates high effectiveness in killing cancer cells while sparing normal cells. The approach has commercial promise due to its broad-spectrum effectiveness across multiple tumor types, positioning the company favorably in the rapidly expanding RNA-based cancer therapeutics market.

BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on cancer diagnostics and targeted therapeutics, recently presented groundbreaking research at the 2025 RNA Therapeutics Conference. The company showcased a potential broad-spectrum cancer therapy that utilizes small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting two specific cell surface receptors, CD320 and LRP2. The study, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that demonstrates high effectiveness in killing cancer cells while sparing normal cells.

The data presented at the conference indicates that dual suppression of these proteins is highly effective in killing cancer cells across multiple tumor types, including lung, breast, prostate, brain, and skin cancers. This broad-spectrum effectiveness positions bioAffinity Technologies favorably within the rapidly expanding market for RNA-based cancer therapeutics. The company's approach leverages siRNAs to selectively silence cell surface proteins, offering significant commercial promise.

David Elzi, PhD, Vice President of Product Development, presented the research on behalf of fellow authors, William Bauta, PhD, Chief Science Officer, and Staff Scientist Reggie Jacob, MS. Dr. Elzi stated, "Our studies show that silencing the cell surface receptors CD320 and LRP2 using siRNAs selectively kills or halts the growth of cancer cells while leaving normal cells unaffected. This effect was observed across multiple cancer types, regardless of mutation status."

Maria Zannes, President and CEO of bioAffinity Technologies, expressed pride in sharing the research with the scientific, academic, and industry leaders at the conference. "This work reflects our commitment to developing novel, highly selective treatments in the battle against cancer," she said.

The RNA Therapeutics Institute at the University of Massachusetts (UMass) T.H. Chan Medical School in Worcester, MA, leverages RNA biology and clinical research to develop new therapeutics for multiple diseases based on the fundamental mechanisms of cellular RNAs. BioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity, and accuracy for the detection of early-stage lung cancer.

The presentation at the 2025 RNA Therapeutics Conference underscores bioAffinity Technologies' commitment to advancing RNA-based cancer therapeutics. The company's approach holds substantial commercial promise due to its broad-spectrum effectiveness and potential to develop targeted therapies that could significantly enhance patient outcomes.

References:
[1] https://ir.bioaffinitytech.com/news-events/press-releases/detail/139/bioaffinity-technologies-scientists-present-breakthrough
[2] https://www.nasdaq.com/articles/actuate-therapeutics-reports-promising-survival-outcomes-phase-2-trial-elraglusib